Estrogen use should be discontinued unless its need outweighs its adverse effects on porphyrin metabolism. After achievement of remission, estrogen therapies may be cautiously reinstituted; however, the duration of remissions may be shortened. Plaquenil causes leg weakness in psoriatic arthritis Is chloroquine safe during pregnancy Hives on my buttocks and thighs plaquenil Porphyria Cutanea Tarda PCT is the most common of the Porphyrias and results from a deficiency of the enzyme uroporphyrinogen decarboxylase UROD. Porphyria Cutanea Tarda PCT is a rare disorder characterized by painful, blistering skin lesions that develop on sun-exposed skin photosensitivity. The treatment for Porphyria Cutanea Tarda involves a procedure called phlebotomy or by taking medication called hydroxychloroquine. Phlebotomy is a procedure in which blood is removed from the body so that the iron levels in the body becomes less which in turn helps in treatment of Porphyria Cutanea Tarda. Most of the symptoms of porphyria cutanea tarda appear on the skin. Common symptoms include blisters on skin that’s exposed to the sun, including the hands, face, and arms. photosensitivity, which means your skin is sensitive to the sun. thin or fragile skin. increased hair growth, usually on the face. If symptoms recur, re-treatment can restore remissions. Remissions may last from several months to many years. Why hydroxychloroquine for porphyria cutanea tarda Low-Dose Hydroxychloroquine Is as Effective as Phlebotomy in Treatment., Porphyria Cutanea TardaCausesSymptomsTreatmentDiagnosis Generic of plaquenil and drynessMferg plaquenil In the treatment of porphyria cutanea tarda, hydroxychloroquine 100 mg should be prescribed twice weekly for one month, then 200 mg/day until plasma porphyrin levels are normal for at least a month. Initial higher doses may lead to hepatotoxicity as a result of rapid mobilisation of hepatic porphyrin stores. Hydroxychloroquine DermNet NZ. Porphyria Cutanea Tarda Pictures, Treatment, and More. Porphyria NIDDK. BACKGROUND & AIMS Porphyria cutanea tarda PCT is an iron-related disorder caused by reduced activity of hepatic uroporphyrinogen decarboxylase; it can be treated by phlebotomy or low doses of hydroxychloroquine. We performed a prospective pilot study to compare the efficacy and safety of these therapies. Porphyria cutanea tarda PCT is an iron-related disorder that results from reduced activity of hepatic uroporphyrinogen decarboxylase. Treatment options include phlebotomy or low doses of hydroxychloroquine. Phlebotomy is expensive, inconvenient, and can increase risk for anemia or syncope. Low-dose hydroxychloroquine is generally as effective as phlebotomy for treatment of PCT, but longer studies are needed to compare relapse rates. Singal AK, Kormos-Hallberg C, Lee C, et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda.